Bijal Shah, MD, Moffit Cancer Center

Advancing the Treatment Landscape in Philadelphia-Positive ALL

August 29th 2023

Key opinion leaders review the evolution of Ph+ ALL treatment, from Hyper-CVAD to novel TKIs, blinatumomab, and deintensification, improving remission rates and survival.

Ph+ ALL Management Updates: Expert Insights

August 29th 2023

Leading experts Bijal Shah, MD, MS, and Hagop Kantarjian, MD, discuss diagnostic challenges, evolving treatments, and prognosis in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

Dr. Shah and Dr. Wang on the Need for Academic and Community Collaboration With CAR T-Cell Therapy

November 24th 2021

Bijal Shah, MD, MS, and Michael Wang, MD, discuss the need for collaboration between academic and community practices for patients who receive CAR T-cell therapy.

Dr. Shah and Dr. Wang on the Challenges of Managing High-Risk MCL

November 24th 2021

Bijal Shah, MD, MS, and Michael Wang, MD, discuss the challenges of managing high-risk mantle cell lymphoma.

Dr. Shah and Dr. Wang on Navigating the Referral Process for CAR T-Cell Therapy in Hematologic Malignancies

November 24th 2021

Bijal Shah, MD, MS, and Michael Wang, MD, discuss navigating the referral process for CAR T-cell therapy in hematologic malignancies.

Dr. Shah and Dr. Wang on Managing CRS and Neurotoxicity in Leukemia/Lymphoma

November 24th 2021

Bijal Shah, MD, MS, and Michael Wang, MD, discuss management strategies for CAR T-cell therapy–related cytokine release syndrome and neurotoxicity in leukemia and lymphoma.

Dr. Shah and Dr. Wang on CAR T-Cell Therapy–Associated Toxicities in Hematologic Malignancies

November 24th 2021

Bijal Shah, MD, MS, and Michael Wang, MD, discuss the main CAR T-cell therapy–associated toxicities in hematologic malignancies.

Dr. Shah on Efforts to Combat Resistance to BTK Inhibitors in MCL

July 7th 2021

Bijal Shah, MD, MS, discusses efforts to combat resistance to BTK inhibitors in patients with mantle cell lymphoma.

Dr. Shah on Shortcomings With BTK Inhibitors in High-Risk MCL

June 3rd 2021

Bijal Shah, MD, MS, discusses shortcomings with BTK inhibitors in high-risk mantle cell lymphoma.

ASH Updates for CAR T-Cell Therapy in Acute Lymphoblastic Leukemia

March 4th 2021

Evolving Field of Acute Lymphoblastic Leukemia

March 4th 2021

Investigational CAR T-Cell Therapy in Acute Lymphoblastic Leukemia

February 25th 2021

CAR T-Cell Therapy Use in Second Line Acute Lymphoblastic Leukemia

February 25th 2021

CAR T-Cell Therapy After First Relapse of Acute Lymphoblastic Leukemia

February 18th 2021

Approach to Managing Relapsed Acute Lymphoblastic Leukemia

February 18th 2021

Role of Transplant in Older Adults With Acute Lymphoblastic Leukemia

February 11th 2021

Managing MRD-Negative Acute Lymphoblastic Leukemia

February 11th 2021

Managing MRD-Positive Acute Lymphoblastic Leukemia

February 4th 2021

Treatment of Acute Lymphoblastic Leukemia in the Community Setting

February 4th 2021

Role of MRD Testing in Acute Lymphoblastic Leukemia

January 28th 2021